Biopharmaceutical company UCB (EBR:UCB) announced on Monday the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship Program.
This program is designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.
Applications for the inaugural HS scholarship program are open at www.ucbhsscholarship.com through September 1, 2026. UCB will award up to 11 scholarships in 2026.
The UCB Hidradenitis Suppurativa Scholarship Program aims to help ease the financial burden associated with education and skills development, including undergraduate or graduate studies, certification programs, trade school, and other career-building pathways.
HS is a chronic, painful, and potentially debilitating inflammatory skin disease with symptoms including nodules, abscesses, and pus-discharging draining tunnels (or sinus tracts leading out of the skin) which typically occur in the armpits, groin, and buttocks.
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
Trellus Health renews licensing agreement with Pfizer
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
GSK secures China approval for Exdensur to treat nasal polyp condition
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
Alloy Therapeutics and Biogen expand partnership with multi-target antisense collaboration
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Boston Scientific receives FDA clearance for Asurys fluid management system
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
Hoth Therapeutics deploys OpenClaw AI platform for drug discovery